Business Wire

LemFi Launches Its Biggest Product Expansion Yet Alongside a New Global Brand, ‘Ambition has no passport’

21.10.2026 09:00:00 CEST | Business Wire | Press Release

Share

LemFi, the financial platform for people building lives across borders, today announced the launch of its new global brand platform, “Ambition has no passport”, alongside a completely rebuilt app, launching the largest product expansion in its history.

More than two million customers use LemFi to move money to more than 30 countries, with over $2 billion in monthly transaction volume, and the company plans to add more countries next year. The expanded platform now includes savings and credit in the UK, eSIMs in more than 100 destinations, alongside LemFi’s existing international payments service.

People who move countries arrive with a career, a qualification and a savings record, only to find that almost none of it counts. A credit history rarely survives a border crossing. Around 304 million people now live outside the country where they were born, sending some $905 billion home each year. Yet many financial services remain designed around individual products or customers living their financial lives in a single country. LemFi is building its platform around that gap, extending from the international transfers on which the company was founded into a wider range of financial services designed for people whose lives span borders.

“We started LemFi because sending money home was broken. What we learned is that the harder problem starts after the transfer,” said Ridwan Olalere, co-founder and CEO of LemFi. “Our customers are building careers and businesses in one country while supporting people in another, and the financial system treats them as if they can only exist in one place at a time. That is the wrong answer for people this ambitious, so we have rebuilt LemFi to work the way their lives do. Ambition travels. The infrastructure behind it should travel too.”

Inside LemFi’s expanded platform

Transfers, still at the heart of it. Send money to more than 30 countries across Africa, Asia, Europe and beyond, from the same account that now saves, borrows and connects.

Savings that stay within reach in the UK. The LemFi Instant Access Savings Account currently pays a boosted 5% AER for the first six months from account opening; it then reverts to 3.04% AER (tracker), tracking the Bank of England base rate. Accounts open from £1, with no penalty for withdrawals. Deposits are held by ClearBank and protected by the Financial Services Compensation Scheme (FSCS) up to £120,000 per eligible depositor.

A credit history that travels in the UK. A revolving credit line, available subject to availability, is issued by Lemfi Credit through Pillar, the FCA-regulated credit provider LemFi acquired in 2025. It is available as a virtual card through Apple Pay and Google Pay and can be used for both spending and sending. Eligible customers can also see their Equifax credit score in the app for free.

eSIM in more than 100 destinations, in every market. Buy mobile data before arriving, with no SIM swap and no roaming bill.

A brand and an app rebuilt together

The app has been re-architected from the ground up to hold several products across several countries in a single account, rather than bolting them onto a transfer app. The redesign also brings LemFi’s products to the forefront of the experience, making them easier to discover and creating an architecture that lets the company add new services as it expands.

The company has also introduced its new global brand platform, “Ambition has no passport”, reflecting its focus on customers building careers, businesses, families and financial lives across borders. The new identity spans LemFi’s product interface, website, marketing and social channels and will roll out across its global markets.

“LemFi started as a way to send money home. Our customers turned it into a way to build a life across borders,” said Isabel Ron-Pedrique, VP of Design and Brand at LemFi. “They are not defined by the country they left. They are defined by what they are building. Ambition has no passport is not a line we placed on top of the product. It is the idea the whole system is built from, from the app you open in the morning to the poster you walk past on the way to work. We have built this brand to keep up with them”

Savings and credit are available in the UK at launch, with other markets to follow.

About LemFi

LemFi is the financial platform for people building lives across borders. Founded in 2021 by Ridwan Olalere and Rian Cochran, LemFi serves more than two million customers, moving money to more than 30 countries across Africa, Asia, Europe and beyond, with around $2 billion in transactions every month. The company has raised more than $85 million from Highland Europe, Left Lane Capital, Palm Drive Capital, Endeavor Catalyst and Y Combinator. www.lemfi.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20261021490151/en/

Contacts

Georgina Trott | georgina@burlington.cc

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye